Olalekan Oluwole, MBBS, MD - The Time Is Now for Outpatient CAR-T: Essential Infrastructure, Lessons From Transplant, and New Evidence

Go online to PeerView.com/NEC860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Although chimeric antigen receptor (CAR-T) cell therapy is
primarily administered in the inpatient setting, delivery in the
outpatient setting likely represents a more convenient and
patient-friendly approach that could expand potentially life-saving
treatment access for many patients with hematologic cancers. This
“Learning Workshop” activity provides learners with the “tools of
the trade” for building an outpatient infrastructure that is
capable of expanding patient access to CAR-T therapy. Expert
panelists discuss the key data supporting CAR-T therapy in
hematologic cancers and provide guidance on principles of
outpatient cellular therapy, lessons derived from the outpatient
experience with stem cell transplantation, and strategies to
overcome barriers to patient selection, adverse events, and
adequate staffing. Upon completion of this activity, participants
should be better able to: Summarize current evidence supporting the
integration of CAR-T constructs into the management of hematologic
cancers, including in earlier and later lines of care; Cite the
infrastructure and design for an outpatient cellular therapy
program and the relevant practical experience from home-based
transplantation initiatives; Develop strategies for optimal patient
selection, staffing, and management of adverse events in the
context of an outpatient cellular therapy program; and Employ tools
such as quality metrics, telemedicine, and wearable devices in an
outpatient cellular therapy program to ensure successful delivery
of CAR-T therapy